TaiGen Biotechnology submits NDA for Taigexyn Intravenous Formulation to CFDA
TaiGen Biotechnology has submitted a New Drug Application (NDA) for Taigexyn (Nemonoxacin)intravenous formulation to China Food and Drug Administration (CFDA).
Taigexyn is a novel…
Read More...
Read More...
